Dr. Ibrahim T. Aldoss, M.D.

Medicare patients and services

Medicare patients, 2024

123

Services billed

876

Patients’ average age

68

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 11 companies reported 51 payments worth $71,785 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 16 industry-funded studies in 2025, from 8 companies. The companies reported $3,071,621 in research payments for these studies, mostly to the institutions running them.

• A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia
  AstraZeneca Pharmaceuticals LP
• Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic…
  Amgen Inc.
• A phase 2 study evaluating the safety and efficacy of first line asparaginase recombinant erwinia asparaginase (Rylaze) during pediatric-inspired regimen in high-risk adults with newly diagnosed ALL or lbl
  Jazz Pharmaceuticals Inc.
• A20-458;Venclexta;Blister Card: ABT-199 100mg Film-coated Tablet 2x8, 16 Tablets
  AbbVie Inc.
• A pilot study combining venetoclax with pediatric-inspired regimen for newly diagnosed young adults with Ph-like acute lymphoblastic leukemia
  AbbVie Inc.
• Asciminib as a maintenance treatment post cellular therapies in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
  Novartis Pharmaceuticals Corporation
• A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia
  Janssen Research & Development, LLC
• A20-458;Venclexta;Blister Card: ABT-199 100mg Tablet, 1x8 Tablets
  AbbVie Inc.
• A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
  Takeda Pharmaceuticals U.S.A., Inc. · Active, not recruiting · NCT03589326
• A phase 1, open-label, dose-escalation, and dose-expansion study to evaluate safety, tolerability, and clinical activity OFSNDX-5613IN combination with intensive chemotherapy in participants with newly diagnosed acute…
  Syndax Pharmaceuticals, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology clinicians in Duarte

• Michelle Afkhami, M.D.
• Mhd Monzr Al Malki, M.D.
• Haris Ali, M.D.
• Joseph C. Alvarnas, M.D.
• Idoroenyi Amanam, M.D.
• Ahmed Aribi, MD
• Andrew S. Artz, M.D., M.S.
• John Baird, MD